BEIJING, Sept. 22,
2022 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman"
or the "Company"), a leading provider of tech-powered, intellectual
development products in China,
today announced its unaudited financial results for the
second quarter ended June 30, 2022.
Second Quarter 2022 Highlights
- Revenues were RMB230.6 million
(US$34.4 million).
- Gross profit was RMB163.2 million
(US$24.4 million).
- Operating income was RMB22.6
million (US$3.4 million), a
remarkable turnaround compared with an operating loss of
RMB3.5 million in the same period
last year.
- Adjusted operating income[1] was RMB24.6 million (US$3.7
million), a significant increase compared with RMB0.8 million in the same period last year.
- Net income was RMB21.8 million
(US$3.3 million), a significant
increase compared with RMB1.9 million
in the same period last year.
- Adjusted net income[1] was RMB23.8 million (US$3.6
million), a significant increase compared with RMB6.1 million in the same period last year.
- Average total MAUs[2] for the quarter were 18.20
million, a year-over-year increase of 17.6%.
Dr. Peng Dai, Director and Chief
Executive Officer of iHuman, commented, "Underpinned by our
industry-leading content portfolio and superior user experience, we
are very pleased to report another solid quarter despite the
seasonality impact on our business. Our average total MAUs achieved
double-digit growth at approximately 18% year over year. Our
success in growing our user base while maintaining a dynamic and
tight-knit community has further increased long-term development
opportunities for our business. During the quarter, we continued to
make progress in promoting the all-around development of children
by optimizing our product portfolio through content enhancements
and new product rollouts. In July
2022, we launched iHuman Writing, a self-directed
Chinese character writing app for kids. When used in conjunction
with the iHuman Smart Writing Pen, one of our smart devices,
the app seamlessly integrates hardware and software to offer
children a new way to engage with handwriting characterized by
paper-screen synchronization, real-time feedback, and a fun
interactive experience. As a new addition to our Chinese-focused
product family, the app represents a natural extension of our
existing product line, which we believe will help further enhance
user engagement and increase their lifetime value. Meanwhile, we
have also been continuously enriching our existing products. For
example, we added two new modules "Universe" and
"Insect" into iHumanpedia. Within the
"Universe" module, children get to travel virtually with the
onscreen protagonists, embark on a space journey, and come across
various fun discoveries. For the "Insect" module, we aim to
get kids more interested in nature, enhance their observation
skills, and cultivate admiration for life. Going forward, we will
remain laser-focused on solidifying our market leadership by
continuing to execute our product-driven growth strategies,
increase market penetration, and continue creating new growth
levers."
Ms. Vivien Weiwei Wang, Director
and Chief Financial Officer of iHuman, added, "We are delighted to
report another profitable quarter with a net income of RMB21.8 million, primarily driven by our
strategies to enhance user engagement and optimize cost efficiency.
In the quarter, our leading product offerings continued to
effectively fulfill the strong market demand as we kept building on
our technology and content capabilities to support children's
cognitive development. In addition, as we mentioned in our first
quarter 2022 earnings release, we started ramping up efforts to
expand our reach in international markets to meet the increasing
demand for high-quality child-upbringing products amongst overseas
families. In the quarter, we officially unveiled our
international-facing brand Bekids, which strives to promote
the well-rounded development of children through STEAM-focused
products. Meanwhile, in addition to our presence on Apple app
stores, we also listed our most popular Chinese-focused apps, such
as iHuman Chinese and iHuman Stories, on Google Play
stores globally, catering specifically to the needs of overseas
families with an aim of arousing their children's interest in
understanding more about the Chinese language and culture. The
dual-track product strategy will enable us to leverage our current
offerings and industry know-how to maximize cross-market synergies.
Moving ahead, we believe our international expansion will support
our sustainable business development and create more value for our
shareholders."
Second Quarter 2022 Unaudited Financial Results
Revenues
Revenues were RMB230.6 million
(US$34.4 million), an increase of
4.2% from RMB221.3 million in the
same period last year, primarily driven by enhanced user
engagement.
Average total MAUs for the quarter were 18.20 million, an
increase of 17.6% year-over-year from 15.47 million in the same
period last year. The number of paying users[3] for the
quarter was 1.51 million.
Cost of Revenues
Cost of revenues was RMB67.4
million (US$10.1 million),
compared with RMB67.0 million in the
same period last year.
Gross Profit and Gross Margin
Gross profit was RMB163.2 million
(US$24.4 million), an increase of
5.8% from RMB154.3 million in the
same period last year. Gross margin was 70.8%, compared with 69.7%
in the same period last year.
Operating Expenses
Total operating expenses were RMB140.6
million (US$21.0 million), a
decrease of 10.9% from RMB157.7
million in the same period last year. Excluding share-based
compensation expenses, total operating expenses were RMB138.6 million, a decrease of 9.9% from the
same period last year.
Research and development expenses were RMB78.2 million (US$11.7
million), a decrease of 16.0% from RMB93.1 million in the same period last year.
Excluding share-based compensation expenses, the research and
development expenses were RMB77.4
million, a decrease of 15.4% from the same period last year,
primarily due to cost saving in payroll-related expenses and
outsourcing expenses.
Sales and marketing expenses were RMB33.5
million (US$5.0 million), a
decrease of 26.0% from RMB45.3
million in the same period last year. Excluding share-based
compensation expenses, the sales and marketing expenses were
RMB33.1 million, a decrease of 25.3%
from the same period last year, primarily due to an economical and
optimized advertising strategy.
General and administrative expenses were RMB28.8 million (US$4.3 million), an increase of 49.0% from
RMB19.4 million in the same period
last year. Excluding share-based compensation expenses, the general
and administrative expenses were RMB28.1
million, an increase of 56.9% from the same period last
year, primarily due to the result of expenses to upgrade the
Company's corporate governance and compliance structure as a
publicly listed company.
Operating Income (Loss)
Operating income was RMB22.6
million (US$3.4 million),
compared with an operating loss of RMB3.5
million in the same period last year.
Excluding share-based compensation expenses, adjusted operating
income was RMB24.6 million
(US$3.7 million), compared with
RMB0.8 million in the same period
last year.
Net Income
Net income was RMB21.8 million
(US$3.3 million), compared with
RMB1.9 million in the same period
last year.
Adjusted net income was RMB23.8
million (US$3.6 million),
compared with RMB6.1 million in the
same period last year.
Basic and diluted net income per ADS were RMB0.41 (US$0.06)
and RMB0.40 (US$0.06), respectively, compared with
RMB0.04 and RMB0.03 in the same period last year. Each ADS
represents five Class A ordinary shares of the Company.
Adjusted diluted net income per ADS was RMB0.44 (US$0.07),
compared with RMB0.11 in the same
period last year.
Deferred Revenue and Customer
Advances
Deferred revenue and customer advances were RMB314.3 million (US$46.9
million) as of June 30, 2022,
compared with RMB303.0 million as of
December 31, 2021.
Cash, Cash Equivalents and Time Deposits
Cash, cash equivalents and time deposits were RMB856.3 million (US$127.8
million) as of June 30, 2022,
compared with RMB855.4 million as of
December 31, 2021.
[1] "Adjusted operating
income" and "adjusted net income" exclude share-based compensation
expenses. Please see "Non-GAAP Financial Measures" and "Unaudited
Reconciliation of GAAP and non-GAAP Results" at the end of this
press release.
|
[2] "Average total
MAUs" refers to the monthly average of the sum of the MAUs of each
of the Company's apps during a specific period, which is counted
based on the number of unique mobile devices through which such app
is accessed at least once in a given month, and duplicate access to
different apps is not eliminated from the total MAUs
calculation.
|
[3] "Paying users"
refers to users who paid subscription fees for premium content on
any of the Company's apps during a specific period; a user who
makes payments across different apps using the same registered
account is counted as one paying user, and a user who makes
payments for the same app multiple times in the same period is
counted as one paying user.
|
Exchange Rate Information
The U.S. dollar (US$) amounts disclosed in this press release,
except for those transaction amounts that were actually settled in
U.S. dollars, are presented solely for the convenience of the
reader. The conversion of Renminbi (RMB) into US$ in this press
release is based on the exchange rate set forth in the H.10
statistical release of the Board of Governors of the Federal
Reserve System as of June 30, 2022,
which was RMB6.6981 to US$1.00. The percentages stated in this press
release are calculated based on the RMB amounts.
Non-GAAP Financial Measures
iHuman considers and uses non-GAAP financial measures, such as
adjusted operating income, adjusted net income and adjusted diluted
net income per ADS, as supplemental metrics in reviewing and
assessing its operating performance and formulating its business
plan. The presentation of non-GAAP financial measures is not
intended to be considered in isolation or as a substitute for the
financial information prepared and presented in accordance with
accounting principles generally accepted in the United States of America ("U.S. GAAP").
iHuman defines adjusted operating income, adjusted net income and
adjusted diluted net income per ADS as operating income, net income
and diluted net income per ADS excluding share-based compensation
expenses, respectively. Adjusted operating income, adjusted net
income and adjusted diluted net income per ADS enable iHuman's
management to assess its operating results without considering the
impact of share-based compensation expenses, which are non-cash
charges. iHuman believes that these non-GAAP financial measures
provide useful information to investors in understanding and
evaluating the Company's current operating performance and
prospects in the same manner as management does, if they so
choose.
Non-GAAP financial measures are not defined under U.S. GAAP and
are not presented in accordance with U.S. GAAP. Non-GAAP financial
measures have limitations as analytical tools, which possibly do
not reflect all items of expense that affect our operations.
Share-based compensation expenses have been and may continue to be
incurred in our business and are not reflected in the presentation
of the non-GAAP financial measures. In addition, the non-GAAP
financial measures iHuman uses may differ from the non-GAAP
measures used by other companies, including peer companies, and
therefore their comparability may be limited. The presentation of
these non-GAAP financial measures is not intended to be considered
in isolation from or as a substitute for the financial information
prepared and presented in accordance with GAAP.
Safe Harbor Statement
This announcement contains forward-looking statements. These
statements are made under the "safe harbor" provisions of the
United States Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by terminology
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar statements.
Statements that are not historical facts, including statements
about iHuman's beliefs and expectations, are forward-looking
statements. Among other things, the description of the management's
quotations in this announcement contains forward-looking
statements. iHuman may also make written or oral forward-looking
statements in its periodic reports to the U.S. Securities and
Exchange Commission (the "SEC"), in its annual report to
shareholders, in press releases and other written materials, and in
oral statements made by its officers, directors or employees to
third parties. Forward-looking statements involve inherent risks
and uncertainties. A number of factors could cause actual results
to differ materially from those contained in any forward-looking
statement, including but not limited to the following: iHuman's
growth strategies; its future business development, financial
condition and results of operations; its ability to continue to
attract and retain users, convert non-paying users into paying
users and increase the spending of paying users, the trends in, and
size of, the market in which iHuman operates; its expectations
regarding demand for, and market acceptance of, its products and
services; its expectations regarding its relationships with
business partners; general economic and business conditions;
regulatory environment; and assumptions underlying or related to
any of the foregoing. Further information regarding these and other
risks is included in iHuman's filings with the SEC. All information
provided in this press release is as of the date of this press
release, and iHuman does not undertake any obligation to update any
forward-looking statement, except as required under applicable
law.
About iHuman Inc.
iHuman Inc. is a leading provider of tech-powered, intellectual
development products in China that
is committed to making the child-rearing experience easier for
parents and transforming cognitive development into a fun journey
for children. Benefiting from a deep legacy that combines over two
decades of experience in the parenthood industry, superior original
content, advanced high-tech innovation DNA and research &
development capabilities with cutting-edge technologies, iHuman
empowers parents with tools to make the child-upbringing experience
more efficient. iHuman's unique, fun and interactive product
offerings stimulate children's natural curiosity and exploration.
The Company's comprehensive suite of innovative and high-quality
products include self-directed apps, interactive content and smart
devices that cover a broad variety of areas to develop children's
abilities in speaking, critical thinking, independent reading and
creativity, and foster their natural interest in traditional
Chinese culture. Leveraging advanced technological capabilities,
including 3D engines, AI/AR functionality, and big data analysis on
children's behavior & psychology, iHuman believes it will
continue to provide superior experience that is efficient and
relieving for parents, and effective and fun for children, in
China and all over the world,
through its integrated suite of tech-powered, intellectual
development products.
For more information about iHuman, please visit
https://ir.ihuman.com/.
For investor and media enquiries, please contact:
iHuman Inc.
Mr. Justin Zhang
Investor Relations Director
Phone: +86 10 5780-6606
E-mail: ir@ihuman.com
Christensen
In China
Mr. Eric Yuan
Phone: +86-13801110739
E-mail: eric.yuan@christensencomms.com
In the US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com
iHuman Inc.
|
UNAUDITED CONDENSED
CONSOLIDATED BALANCE SHEETS
|
(Amounts in
thousands of Renminbi ("RMB") and U.S. dollars
("US$")
|
except for number of
shares, ADSs, per share and per ADS
data)
|
|
|
|
|
|
|
|
December
31,
|
|
June
30,
|
|
June
30,
|
|
2021
|
|
2022
|
|
2022
|
|
RMB
|
|
RMB
|
|
US$
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
Cash and cash
equivalents
|
855,362
|
|
708,683
|
|
105,804
|
Time
deposits
|
-
|
|
147,651
|
|
22,044
|
Accounts receivable,
net
|
56,132
|
|
65,462
|
|
9,773
|
Inventories,
net
|
28,054
|
|
24,165
|
|
3,608
|
Amounts due from
related parties
|
2,845
|
|
5,075
|
|
758
|
Prepayments and other
current assets
|
72,851
|
|
87,895
|
|
13,122
|
Total current
assets
|
1,015,244
|
|
1,038,931
|
|
155,109
|
Non-current
assets
|
|
|
|
|
|
Property and
equipment, net
|
12,286
|
|
10,709
|
|
1,599
|
Intangible assets,
net
|
27,287
|
|
28,252
|
|
4,218
|
Operating
lease right-of-use assets
|
38,237
|
|
21,508
|
|
3,211
|
Long-term
investment
|
-
|
|
26,333
|
|
3,931
|
Amounts due from
related parties
|
4,223
|
|
247
|
|
37
|
Other non-current
assets
|
3,604
|
|
3,381
|
|
505
|
Total non-current
assets
|
85,637
|
|
90,430
|
|
13,501
|
Total
assets
|
1,100,881
|
|
1,129,361
|
|
168,610
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
Accounts
payable
|
30,536
|
|
19,531
|
|
2,916
|
Deferred revenue and
customer advances
|
302,980
|
|
314,332
|
|
46,929
|
Amounts due to related
parties
|
8,853
|
|
21,776
|
|
3,251
|
Accrued expenses and
other current liabilities
|
115,895
|
|
87,037
|
|
12,994
|
Current operating
lease liabilities
|
24,669
|
|
14,603
|
|
2,180
|
Total current
liabilities
|
482,933
|
|
457,279
|
|
68,270
|
Non-current
liabilities
|
|
|
|
|
|
Non-current operating
lease liabilities
|
9,577
|
|
3,495
|
|
522
|
Total non-current
liabilities
|
9,577
|
|
3,495
|
|
522
|
Total
liabilities
|
492,510
|
|
460,774
|
|
68,792
|
SHAREHOLDERS'
EQUITY
|
|
|
|
|
|
Ordinary shares (par
value of US$0.0001 per share,
700,000,000 Class A shares authorized as of
December
31, 2021 and June 30, 2022; 125,122,382 Class A
shares
issued and 123,852,667 outstanding as of December
31,
2021; 125,122,382 Class A shares issued and
122,286,762
outstanding as of June 30, 2022; 200,000,000 Class
B
shares authorized, 144,000,000 Class B ordinary
shares
issued and outstanding as of December 31, 2021 and
June
30, 2022; 100,000,000 shares (undesignated)
authorized,
nil shares (undesignated) issued and outstanding as
of
December 31, 2021 and June 30, 2022)
|
185
|
|
185
|
|
28
|
Additional paid-in
capital
|
1,066,052
|
|
1,070,044
|
|
159,753
|
Treasury
stock
|
(164)
|
|
(5,277)
|
|
(788)
|
Accumulated other
comprehensive loss
|
(34,677)
|
|
(8,248)
|
|
(1,231)
|
Accumulated
deficit
|
(423,025)
|
|
(388,117)
|
|
(57,944)
|
Total shareholders'
equity
|
608,371
|
|
668,587
|
|
99,818
|
Total liabilities
and shareholders' equity
|
1,100,881
|
|
1,129,361
|
|
168,610
|
iHuman Inc.
|
UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
|
(Amounts in
thousands of Renminbi ("RMB") and U.S. dollars
("US$")
|
except for number of
shares, ADSs, per share and per ADS data)
|
|
|
|
|
|
For the three months
ended
|
|
For the six months
ended
|
|
June
30,
|
|
March
31,
|
|
June
30,
|
|
June
30,
|
|
June
30,
|
|
June
30,
|
|
June
30,
|
|
2021
|
|
2022
|
|
2022
|
|
2022
|
|
2021
|
|
2022
|
|
2022
|
|
RMB
|
|
RMB
|
|
RMB
|
|
US$
|
|
RMB
|
|
RMB
|
|
US$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
221,259
|
|
242,679
|
|
230,607
|
|
34,429
|
|
447,917
|
|
473,286
|
|
70,660
|
Cost of
revenues
|
(66,996)
|
|
(72,797)
|
|
(67,417)
|
|
(10,065)
|
|
(132,400)
|
|
(140,214)
|
|
(20,934)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
154,263
|
|
169,882
|
|
163,190
|
|
24,364
|
|
315,517
|
|
333,072
|
|
49,726
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development expenses
|
(93,053)
|
|
(96,625)
|
|
(78,201)
|
|
(11,675)
|
|
(175,165)
|
|
(174,826)
|
|
(26,101)
|
Sales and marketing
expenses
|
(45,298)
|
|
(35,906)
|
|
(33,530)
|
|
(5,006)
|
|
(98,225)
|
|
(69,436)
|
|
(10,367)
|
General and
administrative expenses
|
(19,364)
|
|
(26,058)
|
|
(28,849)
|
|
(4,307)
|
|
(41,933)
|
|
(54,907)
|
|
(8,197)
|
Total operating
expenses
|
(157,715)
|
|
(158,589)
|
|
(140,580)
|
|
(20,988)
|
|
(315,323)
|
|
(299,169)
|
|
(44,665)
|
Operating income
(loss)
|
(3,452)
|
|
11,293
|
|
22,610
|
|
3,376
|
|
194
|
|
33,903
|
|
5,061
|
Other income,
net
|
5,121
|
|
3,347
|
|
2,917
|
|
435
|
|
8,666
|
|
6,264
|
|
935
|
Income before income
taxes
|
1,669
|
|
14,640
|
|
25,527
|
|
3,811
|
|
8,860
|
|
40,167
|
|
5,996
|
Income tax benefit
(expenses)
|
238
|
|
(1,522)
|
|
(3,737)
|
|
(558)
|
|
193
|
|
(5,259)
|
|
(785)
|
Net
income
|
1,907
|
|
13,118
|
|
21,790
|
|
3,253
|
|
9,053
|
|
34,908
|
|
5,211
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per
ADS:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
Basic
|
0.04
|
|
0.25
|
|
0.41
|
|
0.06
|
|
0.17
|
|
0.66
|
|
0.10
|
-
Diluted
|
0.03
|
|
0.24
|
|
0.40
|
|
0.06
|
|
0.16
|
|
0.64
|
|
0.10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of ADSs:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
Basic
|
53,324,476
|
|
53,476,316
|
|
53,308,924
|
|
53,308,924
|
|
53,324,476
|
|
53,392,158
|
|
53,392,158
|
-
Diluted
|
54,680,936
|
|
54,060,837
|
|
53,958,284
|
|
53,958,284
|
|
54,920,644
|
|
54,009,098
|
|
54,009,098
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total share-based
compensation expenses included in:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
revenues
|
257
|
|
64
|
|
39
|
|
6
|
|
524
|
|
103
|
|
15
|
Research and
development expenses
|
1,524
|
|
967
|
|
801
|
|
120
|
|
5,235
|
|
1,768
|
|
264
|
Sales and marketing
expenses
|
986
|
|
(88)
|
|
430
|
|
64
|
|
2,163
|
|
342
|
|
51
|
General and
administrative expenses
|
1,458
|
|
1,014
|
|
762
|
|
114
|
|
3,361
|
|
1,776
|
|
265
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
iHuman Inc.
|
UNAUDITED
RECONCILIATION OF GAAP AND NON-GAAP RESULTS
|
(Amounts in
thousands of Renminbi ("RMB") and U.S. dollars
("US$")
|
except for number of
shares, ADSs, per share and per ADS data)
|
|
|
|
|
|
For the three months
ended
|
|
For the six months
ended
|
|
June
30,
|
|
March
31,
|
|
June
30,
|
|
June
30,
|
|
June
30,
|
|
June
30,
|
|
June
30,
|
|
2021
|
|
2022
|
|
2022
|
|
2022
|
|
2021
|
|
2022
|
|
2022
|
|
RMB
|
|
RMB
|
|
RMB
|
|
US$
|
|
RMB
|
|
RMB
|
|
US$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
(loss)
|
(3,452)
|
|
11,293
|
|
22,610
|
|
3,376
|
|
194
|
|
33,903
|
|
5,061
|
Share-based
compensation expenses
|
4,225
|
|
1,957
|
|
2,032
|
|
304
|
|
11,283
|
|
3,989
|
|
595
|
Adjusted operating
income
|
773
|
|
13,250
|
|
24,642
|
|
3,680
|
|
11,477
|
|
37,892
|
|
5,656
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
income
|
1,907
|
|
13,118
|
|
21,790
|
|
3,253
|
|
9,053
|
|
34,908
|
|
5,211
|
Share-based
compensation expenses
|
4,225
|
|
1,957
|
|
2,032
|
|
304
|
|
11,283
|
|
3,989
|
|
595
|
Adjusted net
income
|
6,132
|
|
15,075
|
|
23,822
|
|
3,557
|
|
20,336
|
|
38,897
|
|
5,806
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income per
ADS
|
0.03
|
|
0.24
|
|
0.40
|
|
0.06
|
|
0.16
|
|
0.64
|
|
0.10
|
Impact of non-GAAP
adjustments
|
0.08
|
|
0.04
|
|
0.04
|
|
0.01
|
|
0.21
|
|
0.08
|
|
0.01
|
Adjusted diluted net
income per ADS
|
0.11
|
|
0.28
|
|
0.44
|
|
0.07
|
|
0.37
|
|
0.72
|
|
0.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number
of ADSs – diluted
|
54,680,936
|
|
54,060,837
|
|
53,958,284
|
|
53,958,284
|
|
54,920,644
|
|
54,009,098
|
|
54,009,098
|
Weighted average
number of ADSs – adjusted
|
54,680,936
|
|
54,060,837
|
|
53,958,284
|
|
53,958,284
|
|
54,920,644
|
|
54,009,098
|
|
54,009,098
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ihuman-inc-announces-second-quarter-2022-unaudited-financial-results-301630512.html
SOURCE iHuman Inc.